These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 21514409)

  • 1. ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans.
    John MR; Widler L; Gamse R; Buhl T; Seuwen K; Breitenstein W; Bruin GJ; Belleli R; Klickstein LB; Kneissel M
    Bone; 2011 Aug; 49(2):233-41. PubMed ID: 21514409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AXT914 a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal women.
    John MR; Harfst E; Loeffler J; Belleli R; Mason J; Bruin GJ; Seuwen K; Klickstein LB; Mindeholm L; Widler L; Kneissel M
    Bone; 2014 Jul; 64():204-10. PubMed ID: 24769332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation.
    Kumar S; Matheny CJ; Hoffman SJ; Marquis RW; Schultz M; Liang X; Vasko JA; Stroup GB; Vaden VR; Haley H; Fox J; DelMar EG; Nemeth EF; Lago AM; Callahan JF; Bhatnagar P; Huffman WF; Gowen M; Yi B; Danoff TM; Fitzpatrick LA
    Bone; 2010 Feb; 46(2):534-42. PubMed ID: 19786130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1-Alkyl-4-phenyl-6-alkoxy-1H-quinazolin-2-ones: a novel series of potent calcium-sensing receptor antagonists.
    Widler L; Altmann E; Beerli R; Breitenstein W; Bouhelal R; Buhl T; Gamse R; Gerspacher M; Halleux C; John MR; Lehmann H; Kalb O; Kneissel M; Missbach M; Müller IR; Reidemeister S; Renaud J; Taillardat A; Tommasi R; Weiler S; Wolf RM; Seuwen K
    J Med Chem; 2010 Mar; 53(5):2250-63. PubMed ID: 20158186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma levels of parathyroid hormone that induce anabolic effects in bone of ovariectomized rats can be achieved by stimulation of endogenous hormone secretion.
    Fox J; Miller MA; Stroup GB; Nemeth EF; Miller SC
    Bone; 1997 Aug; 21(2):163-9. PubMed ID: 9267692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcilytics: antagonists of the calcium-sensing receptor for the treatment of osteoporosis.
    Widler L
    Future Med Chem; 2011 Apr; 3(5):535-47. PubMed ID: 21526895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JTT-305, an orally active calcium-sensing receptor antagonist, stimulates transient parathyroid hormone release and bone formation in ovariectomized rats.
    Kimura S; Nakagawa T; Matsuo Y; Ishida Y; Okamoto Y; Hayashi M
    Eur J Pharmacol; 2011 Oct; 668(1-2):331-6. PubMed ID: 21810422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Normal epidermal growth factor receptor signaling is dispensable for bone anabolic effects of parathyroid hormone.
    Schneider MR; Dahlhoff M; Andrukhova O; Grill J; Glösmann M; Schüler C; Weber K; Wolf E; Erben RG
    Bone; 2012 Jan; 50(1):237-44. PubMed ID: 22056328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infrequent delivery of a long-acting PTH-Fc fusion protein has potent anabolic effects on cortical and cancellous bone.
    Kostenuik PJ; Ferrari S; Pierroz D; Bouxsein M; Morony S; Warmington KS; Adamu S; Geng Z; Grisanti M; Shalhoub V; Martin S; Biddlecome G; Shimamoto G; Boone T; Shen V; Lacey D
    J Bone Miner Res; 2007 Oct; 22(10):1534-47. PubMed ID: 17576164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength.
    Fox J; Miller MA; Newman MK; Metcalfe AF; Turner CH; Recker RR; Smith SY
    Calcif Tissue Int; 2006 Oct; 79(4):262-72. PubMed ID: 16969596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parathyroid hormone increases the concentration of insulin-like growth factor-I and transforming growth factor beta 1 in rat bone.
    Pfeilschifter J; Laukhuf F; Müller-Beckmann B; Blum WF; Pfister T; Ziegler R
    J Clin Invest; 1995 Aug; 96(2):767-74. PubMed ID: 7635970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temporal expression of the anabolic action of PTH in cancellous bone of ovariectomized rats.
    Meng XW; Liang XG; Birchman R; Wu DD; Dempster DW; Lindsay R; Shen V
    J Bone Miner Res; 1996 Apr; 11(4):421-9. PubMed ID: 8992872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parathyroid hormone (1-34) increased total body bone mass in aged female rats.
    Simmons HA; Pirie CM; Thompson DD; Ke HZ
    J Pharmacol Exp Ther; 1998 Jul; 286(1):341-4. PubMed ID: 9655878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the effect of chronic administration of a calcium-sensing receptor antagonist, ronacaleret, on renal calcium excretion and serum calcium in postmenopausal women.
    Caltabiano S; Dollery CT; Hossain M; Kurtinecz MT; Desjardins JP; Favus MJ; Kumar R; Fitzpatrick LA
    Bone; 2013 Sep; 56(1):154-62. PubMed ID: 23756230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel flavonoid C-glucoside from Ulmus wallichiana preserves bone mineral density, microarchitecture and biomechanical properties in the presence of glucocorticoid by promoting osteoblast survival: a comparative study with human parathyroid hormone.
    Khan MP; Mishra JS; Sharan K; Yadav M; Singh AK; Srivastava A; Kumar S; Bhaduaria S; Maurya R; Sanyal S; Chattopadhyay N
    Phytomedicine; 2013 Nov; 20(14):1256-66. PubMed ID: 23928508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monocyte chemoattractant protein-1 is a mediator of the anabolic action of parathyroid hormone on bone.
    Tamasi JA; Vasilov A; Shimizu E; Benton N; Johnson J; Bitel CL; Morrison N; Partridge NC
    J Bone Miner Res; 2013 Sep; 28(9):1975-86. PubMed ID: 23519994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermittent administration of parathyroid hormone (1-37) improves growth and bone mineral density in uremic rats.
    Schmitt CP; Hessing S; Oh J; Weber L; Ochlich P; Mehls O
    Kidney Int; 2000 Apr; 57(4):1484-92. PubMed ID: 10760084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The search for calcium receptor antagonists (calcilytics).
    Nemeth EF
    J Mol Endocrinol; 2002 Aug; 29(1):15-21. PubMed ID: 12200226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein malnutrition attenuates bone anabolic response to PTH in female rats.
    Ammann P; Zacchetti G; Gasser JA; Lavet C; Rizzoli R
    Endocrinology; 2015 Feb; 156(2):419-28. PubMed ID: 25396268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ronacaleret, a calcium-sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal women.
    Fitzpatrick LA; Dabrowski CE; Cicconetti G; Gordon DN; Fuerst T; Engelke K; Genant HK
    J Bone Miner Res; 2012 Feb; 27(2):255-62. PubMed ID: 22052452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.